Navigation Links
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
Date:9/23/2010

t to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.  

ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).  

Under terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets.  Reata will receive upfront and near-term cash payments of $450 million for the licensing rights to bardoxolone and a minority equity investment in the company.  Upon completion of certain development and approval objectives for bardoxolone and other molecules in the licensed territories, Reata will receive additional milestone payments.  Reata also will receive royalties on any future product sales in the Abbott territories.  Additionally, Abbott obtains rights to develop and commercialize certain other Reata compounds for chronic kidney disease, and for cardiovascular and metabolic indications, in these territories.

"Early clinical studies suggest that bardoxolone could be a significant improvement to the current standard of care for CKD and possibly prevent patients from progressing to the later stages of the disease and dialysis," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott.  "This agreement builds on Abbott's existing experience in renal care, while adding a promising compound to our later-stage pipeline."

Bardoxolone is an oral, first-in-class antioxidant inflammation modulator that works by increasing the estimated glomerular filtration rate (eGFR) of the kidneys.
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 4, 2011 Novo Nordisk announced today the ... application (app) to assist in the diagnosis of ... Kessler, MD, Professor of Medicine and Pathology and ... Lombardi Comprehensive Cancer Center. Coags Uncomplicated features a ...
... 4, 2011 /PRNewswire-Asia-FirstCall/ – Lotus Pharmaceuticals, Inc. (OTC Bulletin ... a fast-growing, profitable developer, manufacturer and seller of medicine ... today announced that it will add two additional stories ... which is currently under construction and is scheduled to ...
Cached Medicine Technology:Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders 2Lotus Pharmaceuticals to Expand Construction of Beijing Facility 2Lotus Pharmaceuticals to Expand Construction of Beijing Facility 3
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) ... although this risky behavior remains popular with more than 1.5 million ... 20 percent of high school girls and 5 percent of high ... least once in the previous year, according to the latest poll. ... 7 percent of boys who had done so in 2009. ...
(Date:12/22/2014)... As part of a company-wide ... in San Diego and surrounding areas, Golden ... care team with ongoing online training courses. , ... provided by Caregiverlist®. Caregiverlist® is “the premiere ... most reliable eldercare options, highest quality ratings and ...
(Date:12/22/2014)... Coral Gables, FL (PRWEB) December 22, 2014 ... head lice removal service , Lice Troopers, with its new ... established in southern Florida, takes the hassle out of dealing ... removal services in one of their two salon clinic locations ... home or other location. , The decision to expand developed ...
(Date:12/22/2014)... 22, 2014 On December 22, 2014, ... Pastor Gordon Cashwell for an episode to celebrate Christmas. ... “Why is it so important to you that we ... replies, “We all should respect who Jesus was. I ... on Christian beliefs. That means that on Jesus’ birthday ...
Breaking Medicine News(10 mins):Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Fewer U.S. Teens in Tanning Salons, Study Finds 2Health News:Fewer U.S. Teens in Tanning Salons, Study Finds 3Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2
... of Food Technology magazine designer foods and functional ... mention of micro and macro nutrients// nanonutrients are ... in nanotechnology show great potential for positively influencing ... facilitating the controlled release and protecting the stability ...
... have contained the spread of the bird flu successfully, scientists ... presence// of a live chain of the disease. ,Researchers ... many of the samples are unfit for testing as proper ... ,"Most bird flu samples reaching us remain unfit for ...
... A new study appearing in the April issue of Radiology ... cancers in pregnant women and also assess// the effectiveness of ... Houston have just finished a study where they examined the ... as treated for breast cancer during pregnancy. ,"Ultrasound ...
... Dr Mohie El-Khadem, from Prestbury Avenue, Newcastle-under-Lyme, Staffordshire, was charged ... died shortly after birth at a Shropshire hospital because Dr ... that he used a suction device and forceps because the ... Birmingham Crown Court jury was said that Olivia Rowlings was ...
... next five to ten years may see the development of ... well as heart disease. It also has the added benefit ... currently available to women around the world is a combination ... breast cancer and heart problems such as deep vein thrombosis. ...
... seed lab in Johnston, Iowa, is currently witness to the ... money // and Technological prowess of the United States, ... that is the only succor to a starved African population. ... known U.S. row crop that finds use in animal feed, ...
Cached Medicine News:Health News:Presence Of Live Avian Flu Is A Cause Of Concern: Scientists 2Health News:Ultrasound Can Detect Breast Cancer in Pregnant Women 2Health News:Revolutionary Pill Cuts Risk of Breast Cancer 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: